Common Stock, par value $0.0001 per share
- Symbol
- MGRX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
Mangoceuticals, Inc.
MGRXNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On February 19, 2026, Mangoceuticals, Inc. (the “ Company ”, “ we ” and “ us ”) issued a press release discussing the initial results of sales of our newly launched all-inclusive injectable testosterone replacement therapy (TRT) treatment program. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference.…
Registered securities in this filing
MANGOCEUTICALS, INC. · 8-K · Filed 2026-02-19
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item
7.01 Regulation FD Disclosure.
On
February 19, 2026, Mangoceuticals, Inc. (the “ Company ”, “ we ” and “ us ”)
issued a press release discussing the initial results of sales of our newly launched all-inclusive injectable testosterone replacement
therapy (TRT) treatment program.
The
press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference.
The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “ filed ”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set
forth by specific reference in such filing.
Filed exhibits (1)
Exhibit 99.1 MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program Month over Month Growth of 336% and 54% Reduction in Customer Acquisition Cost (CAC) DALLAS, TX, FEBRUARY 19, 2026 (GLOBE NEWSWIRE) - Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company” or “MangoRx”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that MangoRx has experienced initial success for its newly launched all-inclusive injectable Testosterone Replacement Therapy (TRT) treatment program priced at $99 per month. The new TRT offer includes all doctor visits and medical consultations, lab work and analysis, and the medication to the extent prescribed. More information about MangoRx’s $99 per month offer can be found here at https://trt.mangorx.com/products/trt. Month over month sales of MangoRx’s injectable TRT treatment program have increased 336% since launching in mid-December while at the same time reducing customer acquisition costs by 54%. We believe that this strong mo…
Open exhibit ↗